ACE2-Ig could potently inhibit WT, Kappa, Delta, and B.1.618 trVLP infection, with 50% inhibitory concentrations (IC50s) of 21.05, 9.90, 15.81, and 15.77 ng/mL, indicating that the Kappa, Delta, and B.1.618 variants are still sensitive to inhibition by ACE2-Ig (Fig. 5A, B and C). The gene discussed is ACE2; the disease is infection.